Analysis of Novel Positioning Sensor-assisted Postoperative Position Correction and Effective Prone Time Recorded in Patients With Different Prone Times After Macular Hole Surgery

February 23, 2023 updated by: Bojie Hu, Tianjin Medical University Eye Hospital

A Prospective Study on the Prognosis of the Idiopathic Macular Hole With Different Prone Position Times Assisted by Novel Positioning Sensor

Idiopathic macular hole (IMH) is a fundus disease without clear etiology, most often seen in healthy women over 50 years of age, and is often associated with ocular manifestations such as loss of central vision and visual distortion. It is often associated with loss of central vision, visual distortion, and other ocular manifestations. It is currently treated by vitrectomy combined with internal limiting membranes (ILM) peeling followed by gas filling. A strict prone position for a certain period of time after surgery has a positive effect on the healing of the macular fissure. The need for a strict prone position after IMH has been demonstrated in previous studies (especially when the IMH diameter is >400 μm). However, due to the anti-human mechanics of the face-down position, patient comfort, sleep quality and quality of life are greatly compromised. Therefore, this study designed a smart head position monitoring device to assist patients in maintaining the correct position and recording the effective position time. The study was conducted to determine the shortest prone position time based on macular fissure closure, to minimize the adverse effects of postoperative position, and to obtain the maximum recovery of visual acuity and visual field.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

86

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Tianjin
      • Tianjin, Tianjin, China
        • Recruiting
        • Tianjin medical university eye hosipital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients aged 18 years or older;
  • Patients diagnosed with IMH;
  • Patients requiring face-down position after vitrectomy combined with ILM peeling and C3F8(14%) gas filling; Tolerated face-down position after surgery;
  • Agreed to the study protocol.

Exclusion Criteria:

  • Myopia greater than or equal to -6.0 D; Eye axis length (AL) greater than 26.0mm;
  • Trauma, macular edema, macular degeneration, and other secondary MH with clear etiology;
  • Previous history of internal eye surgery in the operated eye;
  • Patients with local or systemic other diseases significantly affecting visual function;
  • Those who cannot maintain face-down position after surgery due to systemic factors, etc.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Face-down position time 1-day group
Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
Active Comparator: Face-down position time 3-day group
Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Macular hole closure rate
Time Frame: 6 month postoperatively
Ratio of patients with postoperative lacunae that remained closed until the end of the follow-up time to the number of patients who reopened during the follow-up time of those who did not close after surgery
6 month postoperatively
Effective face-down position time
Time Frame: 1 or 3 day postoperatively
Novel positioning sensor related data cloud storage platform can record and extract effective face-down position time.
1 or 3 day postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Best corrected visual acuity change (BCVA)
Time Frame: 1, 3, 6 month postoperatively
BCVA for patients after macular fissure surgery, expressed using the (ETDRS) Alphabet Chart.
1, 3, 6 month postoperatively
Retinal nerve fiber layer thickness change
Time Frame: 1, 3, 6 month postoperatively
Three-dimensional spectral domain optical coherence tomography (SD-OCT)
1, 3, 6 month postoperatively
Macular ganglion cell complex thickness change (GCL+, GCL++)
Time Frame: 1, 3, 6 month postoperatively
Three-dimensional spectral domain optical coherence tomography (SD-OCT)
1, 3, 6 month postoperatively
Mean retinal Sensitivity (MS)
Time Frame: 1, 3, 6 month postoperatively
Micro Perimeter 3
1, 3, 6 month postoperatively
Central 2˚ and 4˚ fixation
Time Frame: 1, 3, 6 month postoperatively
Micro Perimeter 3
1, 3, 6 month postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2022

Primary Completion (Anticipated)

March 30, 2024

Study Completion (Anticipated)

March 30, 2024

Study Registration Dates

First Submitted

February 14, 2023

First Submitted That Met QC Criteria

February 23, 2023

First Posted (Estimate)

March 7, 2023

Study Record Updates

Last Update Posted (Estimate)

March 7, 2023

Last Update Submitted That Met QC Criteria

February 23, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TianjinMUEHhbj456

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Idiopathic Macular Hole

Clinical Trials on Face-down position time 1-day

Subscribe